{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T03:27:16Z","timestamp":1792207636139,"version":"4.4.0"},"reference-count":90,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2005,10,4]],"date-time":"2005-10-04T00:00:00Z","timestamp":1128384000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Br J Haematol"],"published-print":{"date-parts":[[2005,12]]},"abstract":"<jats:title>Summary<\/jats:title><jats:p>Acute lymphoblastic leukaemia (ALL) is the most common childhood cancer. Treatment has improved but relapsed ALL remains more common than new cases of many \u2018common\u2019 paediatric malignancies. We have salvage regimens with substantial complete remission (CR) rates and increasing access to haematopoietic stem cell transplantation, but most patients who relapse die. We need better therapies. Insights into pharmacology may guide more effective use of existing agents. Novel agents with activity against resistant lymphoblasts offer an appealing strategy. However, most candidate agents fail, despite enthusiastic investigators, intriguing mechanisms of action and \u2018compelling\u2019 preclinical data. A number of existing combinations provide a 40% complete response rate in second or third relapse. Yet survival in third remission is &lt;10%. Novel agents must, most likely, be integrated into multiagent combinations that provide a higher CR rate or better quality CR's than our conventional combinations in order to contribute substantially to cure. The march from bench to bedside requires careful consideration of the intermediate steps.<\/jats:p>","DOI":"10.1111\/j.1365-2141.2005.05773.x","type":"journal-article","created":{"date-parts":[[2005,10,4]],"date-time":"2005-10-04T08:16:10Z","timestamp":1128413770000},"page":"579-587","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":173,"title":["Childhood acute lymphoblastic leukaemia and relapse"],"prefix":"10.1111","volume":"131","author":[{"given":"Paul S.","family":"Gaynon","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2005,10,4]]},"reference":[{"key":"e_1_2_2_2_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V96.5.1709"},{"key":"e_1_2_2_3_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200004063421402"},{"key":"e_1_2_2_4_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2004-05-2023"},{"key":"e_1_2_2_5_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V77.7.1423.1423"},{"key":"e_1_2_2_6_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2402552"},{"key":"e_1_2_2_7_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199411103311902"},{"key":"e_1_2_2_8_1","doi-asserted-by":"publisher","DOI":"10.1002\/mpo.2950110102"},{"key":"e_1_2_2_9_1","doi-asserted-by":"publisher","DOI":"10.1097\/00043426-199701000-00010"},{"key":"e_1_2_2_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1079-9796(03)00072-X"},{"key":"e_1_2_2_11_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2003.02.053"},{"key":"e_1_2_2_12_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V101.10.3835"},{"key":"e_1_2_2_13_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2002-08-2454"},{"key":"e_1_2_2_14_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1999.17.1.197"},{"key":"e_1_2_2_15_1","doi-asserted-by":"publisher","DOI":"10.1097\/00043426-200105000-00010"},{"key":"e_1_2_2_16_1","doi-asserted-by":"publisher","DOI":"10.1002\/mpo.2950210703"},{"key":"e_1_2_2_17_1","first-page":"308","article-title":"Development of targeted therapies in cancer and leukemia","volume":"43","author":"Capdeville R.","year":"2004","journal-title":"Pediatric Blood & Cancer"},{"key":"e_1_2_2_18_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2004-04-1552"},{"key":"e_1_2_2_19_1","first-page":"3982S","article-title":"Epratuzumab, a humanized monoclonal antibody targeting CD22: characterization of in vitro properties","volume":"9","author":"Carnahan J.","year":"2003","journal-title":"Clinical Cancer Research"},{"key":"e_1_2_2_20_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.2003.04584.x"},{"key":"e_1_2_2_21_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2403283"},{"key":"e_1_2_2_22_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2001.19.12.3091"},{"key":"e_1_2_2_23_1","doi-asserted-by":"publisher","DOI":"10.1097\/00043426-199502000-00006"},{"key":"e_1_2_2_24_1","doi-asserted-by":"publisher","DOI":"10.1358\/dot.2005.41.1.875776"},{"key":"e_1_2_2_25_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V84.9.3105.3105"},{"key":"e_1_2_2_26_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V78.10.2780.2780"},{"key":"e_1_2_2_27_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V99.8.2734"},{"key":"e_1_2_2_28_1","doi-asserted-by":"publisher","DOI":"10.1517\/14728222.8.6.551"},{"key":"e_1_2_2_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(01)06355-3"},{"key":"e_1_2_2_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(04)17089-X"},{"key":"e_1_2_2_31_1","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0142(19980401)82:7<1387::AID-CNCR24>3.0.CO;2-1"},{"key":"e_1_2_2_32_1","first-page":"628a","article-title":"Asparagine depletion (ASN) and treatment response in childhood acute lymphoblastic leukemia (ALL) after an early marrow relapse: a Children's Cancer Group trial (CCG\u20101941)","volume":"94","author":"Gaynon P.S.","year":"1999","journal-title":"Blood"},{"key":"e_1_2_2_33_1","first-page":"418a","article-title":"Chemotherapy (CT) vs BMT for children (PTS) with acute lymphoblastic leukemia (ALL) and early marrow relapse (MR): CCG\u20101941","volume":"96","author":"Gaynon P.S.","year":"2000","journal-title":"Blood"},{"key":"e_1_2_2_34_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2401939"},{"key":"e_1_2_2_35_1","doi-asserted-by":"publisher","DOI":"10.1053\/beha.2002.0185"},{"key":"e_1_2_2_36_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.2003.04394.x"},{"key":"e_1_2_2_37_1","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0142(19971215)80:12<2321::AID-CNCR14>3.0.CO;2-W"},{"key":"e_1_2_2_38_1","doi-asserted-by":"publisher","DOI":"10.3109\/08880019809018313"},{"key":"e_1_2_2_39_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.293.24.2985"},{"key":"e_1_2_2_40_1","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1096-911X(199804)30:4<233::AID-MPO5>3.0.CO;2-H"},{"key":"e_1_2_2_41_1","doi-asserted-by":"publisher","DOI":"10.1023\/A:1008381801403"},{"key":"e_1_2_2_42_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2004.04948.x"},{"key":"e_1_2_2_43_1","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1182\/blood.V78.5.1166.1166","article-title":"Six\u2010year experience with a comprehensive approach to the treatment of recurrent childhood acute lymphoblastic leukemia (ALL\u2010REZ BFM 85). A relapse study of the BFM group","volume":"78","author":"Henze G.","year":"1991","journal-title":"Blood"},{"key":"e_1_2_2_44_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2004-11-4296"},{"key":"e_1_2_2_45_1","first-page":"255","article-title":"Case\u2013control analysis of allogeneic bone marrow transplantation versus maintenance chemotherapy for relapsed ALL in children","volume":"15","author":"Hoogerbrugge P.M.","year":"1995","journal-title":"Bone Marrow Transplantation"},{"key":"e_1_2_2_46_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1988.6.2.308"},{"key":"e_1_2_2_47_1","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-642-18930-2_20"},{"key":"e_1_2_2_48_1","first-page":"3646","article-title":"Testing of new agents in childhood cancer preclinical models: meeting summary","volume":"8","author":"Houghton P.J.","year":"2002","journal-title":"Clinical Cancer Research"},{"issue":"1","key":"e_1_2_2_49_1","first-page":"S32","article-title":"Integration of novel agents in the treatment of colorectal cancer","volume":"54","author":"Iqbal S.","year":"2004","journal-title":"Cancer Chemotherapy and Pharmacology"},{"key":"e_1_2_2_50_1","doi-asserted-by":"publisher","DOI":"10.3322\/canjclin.54.1.8"},{"key":"e_1_2_2_51_1","doi-asserted-by":"publisher","DOI":"10.1054\/bjoc.2001.1796"},{"key":"e_1_2_2_52_1","doi-asserted-by":"crossref","first-page":"2546","DOI":"10.1182\/blood.V85.9.2546.bloodjournal8592546","article-title":"Mutations of the p53 and ras genes in childhood t(1;19)\u2010acute lymphoblastic leukemia","volume":"85","author":"Kawamura M.","year":"1995","journal-title":"Blood"},{"key":"e_1_2_2_53_1","doi-asserted-by":"publisher","DOI":"10.1586\/14737140.1.2.177"},{"key":"e_1_2_2_54_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V86.10.3861.bloodjournal86103861"},{"key":"e_1_2_2_55_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V92.11.4072"},{"key":"e_1_2_2_56_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2403097"},{"key":"e_1_2_2_57_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1704241"},{"key":"e_1_2_2_58_1","first-page":"325","article-title":"PEG\u2010l\u2010asparaginase (PEGasp) vs native E. coli asparaginase (asp) for reinduction of relapsed acute lymphoblastic leukemia (ALL): Pediatric Oncology Group (POG) 8866 Phase II trial","volume":"12","author":"Kurtzberg J.","year":"1993","journal-title":"Proceedings of the American Society of Clinical Oncology"},{"key":"e_1_2_2_59_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11912-005-0059-0"},{"key":"e_1_2_2_60_1","first-page":"1143","article-title":"Low\u2010dose intravenous alemtuzumab therapy in pretreated patients affected by chronic lymphocytic leukemia. A single center experience","volume":"90","author":"Laurenti L.","year":"2005","journal-title":"Haematologica"},{"key":"e_1_2_2_61_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.2000.01891.x"},{"key":"e_1_2_2_62_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccr.2005.03.002"},{"key":"e_1_2_2_63_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V87.3.1155.bloodjournal8731155"},{"key":"e_1_2_2_64_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1997.15.3.1158"},{"key":"e_1_2_2_65_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.04.173"},{"key":"e_1_2_2_66_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2000.18.18.3262"},{"key":"e_1_2_2_67_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2005.05509.x"},{"key":"e_1_2_2_68_1","first-page":"768","article-title":"Molecular evidence for minimal residual bone marrow disease in children with \u2018isolated\u2019 extra\u2010medullary relapse of T\u2010cell acute lymphoblastic leukemia","volume":"8","author":"Neale G.A.","year":"1994","journal-title":"Leukemia"},{"key":"e_1_2_2_69_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2796.2003.01098.x"},{"key":"e_1_2_2_70_1","first-page":"624","article-title":"Correlation of bone marrow minimal residual disease and apparent isolated extramedullary relapse in childhood acute lymphoblastic leukaemia","volume":"9","author":"O'Reilly J.","year":"1995","journal-title":"Leukemia"},{"key":"e_1_2_2_71_1","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19930315)71:6<2119::AID-CNCR2820710629>3.0.CO;2-Y"},{"key":"e_1_2_2_72_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(02)08782-2"},{"key":"e_1_2_2_73_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1999.17.12.3745"},{"key":"e_1_2_2_74_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.20743"},{"key":"e_1_2_2_75_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.292.17.2130"},{"key":"e_1_2_2_76_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2005.05572.x"},{"key":"e_1_2_2_77_1","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.20166"},{"issue":"2","key":"e_1_2_2_78_1","first-page":"28","article-title":"Allogeneic BMT vs. chemotherapy in late bone marrow relapsed childhood non\u2010T\/non\u2010B ALL: results of BFM ALL relapse studies. BFM Relapse Study Group","volume":"18","author":"Schmid H.","year":"1996","journal-title":"Bone Marrow Transplantation"},{"issue":"1","key":"e_1_2_2_79_1","first-page":"S121","article-title":"Evolution of BFM trials for childhood ALL","volume":"83","author":"Schrappe M.","year":"2004","journal-title":"Annals of Hematology"},{"key":"e_1_2_2_80_1","doi-asserted-by":"publisher","DOI":"10.1002\/mpo.2950250503"},{"key":"e_1_2_2_81_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1701617"},{"key":"e_1_2_2_82_1","first-page":"224a","article-title":"Early treatment intensification improves outcome in children with acute lymphoblastic leukemia (ALL) and unfavorable features who show a rapid early response (RER) to induction chemotherapy: a report of CCG\u20101961","volume":"102","author":"Seibel N.L.","year":"2003","journal-title":"Blood"},{"key":"e_1_2_2_83_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V97.5.1211"},{"key":"e_1_2_2_84_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2004.01.946"},{"key":"e_1_2_2_85_1","first-page":"36a","article-title":"Comparison of mercaptopurine with thioguanine and IT methotrexate with IT \u2018\u2018triples\u2019\u2019 in children with standard risk (SR) ALL: results of CCG\u20101952","volume":"100","author":"Stork L.C.","year":"2002","journal-title":"Blood"},{"key":"e_1_2_2_86_1","first-page":"801","article-title":"Gene expression profiles and risk stratification in childhood acute lymphoblastic leukemia","volume":"89","author":"Teuffel O.","year":"2004","journal-title":"Haematologica"},{"key":"e_1_2_2_87_1","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1200\/JCO.1995.13.2.352","article-title":"Treatment of childhood acute lymphoblastic leukemia in second remission with allogeneic bone marrow transplantation and chemotherapy: ten\u2010year experience of the Italian Bone Marrow Transplantation Group and the Italian Pediatric Hematology Oncology Association","volume":"13","author":"Uderzo C.","year":"1995","journal-title":"Journal of Clinical Oncology"},{"key":"e_1_2_2_88_1","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1200\/JCO.1985.3.7.998","article-title":"Sequential high\u2010dose cytosine arabinoside\u2010asparaginase treatment in advanced childhood leukemia","volume":"3","author":"Wells R.J.","year":"1985","journal-title":"Journal of Clinical Oncology"},{"key":"e_1_2_2_89_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.1998.00676.x"},{"key":"e_1_2_2_90_1","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19860715)58:2 <598::AID-CNCR2820581332>3.0.CO;2-C"},{"key":"e_1_2_2_91_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.seminoncol.2005.01.008"}],"container-title":["British Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1365-2141.2005.05773.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1365-2141.2005.05773.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,16]],"date-time":"2023-10-16T03:01:15Z","timestamp":1697425275000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1365-2141.2005.05773.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,10,4]]},"references-count":90,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2005,12]]}},"alternative-id":["10.1111\/j.1365-2141.2005.05773.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1365-2141.2005.05773.x","archive":["Portico"],"relation":{},"ISSN":["0007-1048","1365-2141"],"issn-type":[{"value":"0007-1048","type":"print"},{"value":"1365-2141","type":"electronic"}],"subject":[],"published":{"date-parts":[[2005,10,4]]},"assertion":[{"value":"2005-10-04","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}